These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

528 related articles for article (PubMed ID: 30614479)

  • 21. Immune checkpoint inhibitors renal side effects and management.
    Rassy EE; Kourie HR; Rizkallah J; Karak FE; Hanna C; Chelala DN; Ghosn M
    Immunotherapy; 2016 Dec; 8(12):1417-1425. PubMed ID: 28000536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Diagnosis and Treatment Recommendation and Exploration for Critical and Refractory Adverse Effects Related to Immunocheckpoint Inhibitors].
    Wang H; Song P; Si X; Guo X; Li Y; Zhou J; Duan L; Zhang L; Wang M; Zhang L
    Zhongguo Fei Ai Za Zhi; 2019 Oct; 22(10):605-614. PubMed ID: 31650941
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Toxicities of immune checkpoint inhibitors and their management].
    Kostine M; Marabelle A; Schaeverbeke T; Kfoury M
    Med Sci (Paris); 2019 Dec; 35(12):949-956. PubMed ID: 31903899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
    O'Kane GM; Labbé C; Doherty MK; Young K; Albaba H; Leighl NB
    Oncologist; 2017 Jan; 22(1):70-80. PubMed ID: 27534573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Managing Adverse Events With Immune Checkpoint Agents.
    Dadu R; Zobniw C; Diab A
    Cancer J; 2016; 22(2):121-9. PubMed ID: 27111908
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Review article: immune checkpoint inhibitors and the liver, from therapeutic efficacy to side effects.
    Lombardi A; Mondelli MU
    Aliment Pharmacol Ther; 2019 Oct; 50(8):872-884. PubMed ID: 31378985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The development of immunotherapy in older adults: New treatments, new toxicities?
    Helissey C; Vicier C; Champiat S
    J Geriatr Oncol; 2016 Sep; 7(5):325-33. PubMed ID: 27318796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.
    Plachouri KM; Vryzaki E; Georgiou S
    Curr Drug Saf; 2019; 14(1):14-20. PubMed ID: 30058498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recognizing and managing on toxicities in cancer immunotherapy.
    Yang L; Yu H; Dong S; Zhong Y; Hu S
    Tumour Biol; 2017 Mar; 39(3):1010428317694542. PubMed ID: 28351299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine side effects induced by immune checkpoint inhibitors.
    Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
    J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Management of skin adverse events associated with immune checkpoint inhibitors in patients with melanoma: A nursing perspective.
    Thebeau M; Rubin K; Hofmann M; Grimm J; Weinstein A; Choi JN
    J Am Assoc Nurse Pract; 2017 May; 29(5):294-303. PubMed ID: 28436601
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Immunotherapy - immune-related adverse events and their management].
    Petrausch U
    Ther Umsch; 2019 Sep; 76(4):195-198. PubMed ID: 31498041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment after progression in the era of immunotherapy.
    Billan S; Kaidar-Person O; Gil Z
    Lancet Oncol; 2020 Oct; 21(10):e463-e476. PubMed ID: 33002442
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Management of immune-related adverse events during treatment with immune checkpoint inhibitors].
    Queirolo P; Spagnolo F
    Recenti Prog Med; 2016 Aug; 107(8):407-13. PubMed ID: 27571555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.
    Gutierrez C; McEvoy C; Munshi L; Stephens RS; Detsky ME; Nates JL; Pastores SM
    Crit Care Med; 2020 Jan; 48(1):10-21. PubMed ID: 31725440
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dermatologic adverse events of checkpoint inhibitors: what an oncologist should know.
    Habre M; Habre SB; Kourie HR
    Immunotherapy; 2016 Dec; 8(12):1437-1446. PubMed ID: 28000535
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.
    Abdel-Rahman O; Eltobgy M; Oweira H; Giryes A; Tekbas A; Decker M
    Immunotherapy; 2017 Nov; 9(14):1175-1183. PubMed ID: 29067884
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment].
    Szekanecz É; Szekanecz Z
    Orv Hetil; 2019 Jun; 160(23):887-895. PubMed ID: 31155880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Management of Immune Checkpoint Inhibitor Toxicities: A Review and Clinical Guideline for Emergency Physicians.
    Hryniewicki AT; Wang C; Shatsky RA; Coyne CJ
    J Emerg Med; 2018 Oct; 55(4):489-502. PubMed ID: 30120013
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.